• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Costimulatory blockade with belatacept in clinical and experimental transplantation - a review.
【24h】

Costimulatory blockade with belatacept in clinical and experimental transplantation - a review.

机译：贝拉西普在临床和实验移植中的共刺激封锁-综述。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Current maintenance immunosuppression agents have been critical to the improved graft and patient survival rates in solid organ transplantation observed over the past decade. However, long-term follow-up has revealed that these agents are associated with troublesome side effects and chronic toxicity, contributing to graft loss and death. OBJECTIVES: Costimulation blockade has long been recognized as an important target for immunomodulation in solid organ transplantation. Belatacept, a high-affinity chimeric fusion protein that binds to CD80/CD86 on antigen-presenting cells, has shown great promise in renal transplantation and is now in Phase III trials. METHODS: This review explores the development and efficacy of belatacept, compared with currently approved immunosuppressive agents used in transplantation. RESULTS: Belatacept seems to be an effective alternative to current maintenance immunosuppressive therapies, with no apparent end organ toxicity and a minimal side-effect profile. This agent works best when used in combination with therapies that target different pathways of T-cell activation, but the optimal regimen has not yet been identified. Data generated in ongoing clinical trials will be essential in validating previous studies and for further development of belatacept-based combinatorial strategies.
机译：背景：过去十年来，目前维持免疫抑制剂对于提高实体器官移植的移植物和患者存活率至关重要。然而，长期随访发现这些药物与麻烦的副作用和慢性毒性有关，导致移植物丢失和死亡。目的：长期以来，共刺激阻断一直被认为是实体器官移植中免疫调节的重要目标。 Belatacept是一种高亲和力的嵌合融合蛋白，可与抗原呈递细胞上的CD80 / CD86结合，已在肾移植中显示出广阔的前景，目前处于III期试验中。方法：本综述探讨了贝拉西普的发展和功效，与目前批准的用于移植的免疫抑制剂相比。结果：Belatacept似乎是目前维持免疫抑制疗法的有效替代方法，没有明显的终末器官毒性，并且副作用最小。当与靶向T细胞活化不同途径的疗法联合使用时，该药效果最佳，但尚未确定最佳方案。正在进行的临床试验中产生的数据对于验证以前的研究以及进一步开发基于贝拉西普的组合策略至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号